Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer – The View From Goodwin (Chambers Associate)

Related Content

FDA approves Regeneron’s PASATRU™ (garetosmab-grts) for Fibrodysplasia Ossificans Progressiva

FDA Addresses FAQs on Developing Potential Cellular and Gene Therapy Products

Takeda Files BPCIA Suit Against Polpharma Biologics For Vedolizumab Biosimilar

Biocon Announces Supplemental U.S. FDA Approval for Prefilled Autoinjector for YESINTEK

Biocon Launches Aflibercept Biosimilar in the United States

$46 Million Veloxis Settlement Yields Record Sunshine Penalty and Insights Into DOJ’s Cross-Agency Data Use

Deadline Approaching: OIG Seeks Input on Anti-Kickback Safe Harbors for Clinical Trial Participant Remuneration

FDA Approves Moderna’s mFLUSIVA (mRNA-1010) Seasonal Influenza Vaccine

Goodwin Pharma Services Symposium

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Advises Aureka Biotechnologies on Intellectual Property Aspects for $100 Million Series B

Goodwin Advises Amylyx Pharmaceuticals on $575 Million Public Offering

Goodwin Advises AbCellera Biologics on $200 Million Public Offering

Goodwin Advises Fulcrum Therapeutics on Merger with Slate Medicines and $245 Million Private Placement Financing

Goodwin Advises the Underwriters on Silence’s $201 Million Public Offering

Goodwin Advises Zealand Pharma on Entering Into a $100 Million Royalty Purchase and Sale Agreement With Royalty Pharma for the Economics Related to rusfertide

Life Sciences

Intellectual Property